Demegen Licenses Compounds for Oral Diseases to Pacgen

March 23, 2005

Demegen, Inc., a biotechnology company specializing in the development of peptides for the treatment of infectious diseases, announced it had granted a license to Pacgen Biopharmaceuticals Corporation for certain Demegen peptides for prescription and over-the-counter pharmaceutical products to treat oral diseases. Pacgen's initial focus will be a treatment for oral candidiasis, for which Demegen already has an approved IND.

PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/03-22-2005/0003239528&EDATE=)